Bank of America (BofA) has revised its price target for Organon (OGN, Financial), reducing it from $15 to $11, while maintaining an Underperform rating on the company's stock. This adjustment comes as part of BofA's broader analysis of first-quarter earnings updates within the commercial-stage biopharmaceutical sector.
The firm highlights that the first quarter is usually the most complex for this sector due to seasonal influences. Many companies often receive leniency with the expectation that their growth and overall annual performance will be more prominent in the second half of the year. Additionally, BofA suggests that the first-quarter results might be overshadowed by broader economic issues, such as concerns about pharmaceutical tariffs.
This outlook signals potential challenges ahead for Organon and the broader biopharma industry as they navigate these intricate market dynamics.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Organon & Co (OGN, Financial) is $20.40 with a high estimate of $29.00 and a low estimate of $15.00. The average target implies an upside of 84.20% from the current price of $11.08. More detailed estimate data can be found on the Organon & Co (OGN) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Organon & Co's (OGN, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Organon & Co (OGN, Financial) in one year is $20.72, suggesting a upside of 87.09% from the current price of $11.075. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Organon & Co (OGN) Summary page.
